[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"femoropopliteal-artery-occlusion\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:femoropopliteal-artery-occlusion":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100624182","early-phase-1-a-comparative-analysis-of-mid--to-long-term-outcomes-paclitaxel-coated-balloon-with-debulking-versus-paclitaxel-coated-balloon-alone-in-the-treatment-of-chronic-femoropopliteal-artery-occlusions-100624182",false,"NCT07406308","A Comparative Analysis of Mid- to Long-Term Outcomes: Paclitaxel-Coated Balloon With Debulking Versus Paclitaxel-Coated Balloon Alone in the Treatment of Chronic Femoropopliteal Artery Occlusions","A Comparative Analysis of Mid- to Long-Term Outcomes of Paclitaxel-Coated Balloon Angioplasty With Adjunctive Debulking Versus Paclitaxel-Coated Balloon Angioplasty Alone for the Treatment of Chronic Femoropopliteal Artery Occlusions","DCB-Debulk-COM","Inclusion Criteria:\n\n* Subject age 18-85yrs.\n* Subject has been informed of the nature of the study, agrees to participate, and has signed a Medical Ethics Committee approved consent form.\n* Subject understands the duration of the study, agrees to attend follow-up visits, and agrees to complete the required testing.\n* Rutherford category 2-5.\n* Subject has atherosclerotic de novo, non-stented restenotic, or in-stent restenotic\u002Focclusive lesions in the superficial femoral artery (SFA) and\u002For popliteal artery (P1 segment).\n* Patent inflow artery with stenosis \\\u003C30% by visual estimation (or by core lab assessment if available) and at least 1 infrapopliteal artery to the ankle (\\\u003C50% diameter stenosis).\n* A guidewire has successfully traversed the target treatment segment.\n\nExclusion Criteria:\n\n* Subject presents with acute arterial embolism or thrombosis requiring thrombectomy or thrombolysis for limb ischemia.\n* Subject has arterial occlusion caused by thromboangiitis obliterans (Buerger's disease) or other forms of immune-mediated vasculitis.\n* Subject has undergone surgery on the target vessel within the past 3 months, or has experienced repeated failures of endovascular therapy and is deemed unsuitable for further endovascular intervention.\n* Subject has an uncontrolled thrombophilia or hypercoagulable state.\n* Subject has a severe systemic disease (e.g., malignancy) with a life expectancy of less than 1 year.\n* Subject has contraindications or intolerance to antiplatelet\u002Fanticoagulant medications, such as aspirin, clopidogrel, or heparin.\n* Subject is pregnant or breastfeeding.\n* Subject meets one or more of the following conditions: chronic renal insufficiency (SCr ≥ 2.5 mg\u002FdL) or on regular dialysis; cardiovascular or cerebrovascular surgery within the past 1 month; or severe sequelae from a major stroke.\n* Subject has a known allergy to nitinol alloy, paclitaxel, or contrast agents.","ALL","18 Years","85 Years",{"count":21,"type":22},408,"ESTIMATED","INTERVENTIONAL",[25],"EARLY_PHASE1","This study aims to compare mid-to long-term outcomes of paclitaxel-coated balloon angioplasty with adjunctive debulking versus paclitaxel-coated balloon angioplasty alone for the treatment of chronic femoropopliteal artery diseases.",[28],"Femoropopliteal Artery Occlusion",[28,30,31],"Drug-Coated Balloon","debulking procedures","NOT_YET_RECRUITING","2026-02-05",{"date":35,"type":36},"2026-02-12","ACTUAL",{"date":38,"type":22},"2026-04-20",{"date":40,"type":22},"2028-05-30",{"name":42,"class":43},"Peking Union Medical College Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":56,"conditions":57,"keywords":62,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":44},"100522426","framed-infrainguinal-venous-bypass-versus-conventional-autologous-bypass-trial-100522426","NCT06082466","FRAMED Infrainguinal Venous Bypass Versus Conventional Autologous Bypass Trial","Framed IVB","Inclusion Criteria\n\n* Age at least 18 years\n* Informed consent form with signature\n* Rutherford Category 3 (\\\u003C200m) or chronic critical ischemia (Rutherford Category 4-6)\n* Assured inflow and recipient artery.\n\nExclusion Criteria\n\n* Pregnant or breastfeeding women\n* Active infection or sepsis\n* Acute ischemia\n* Endovascular procedure in the region to be treated.\n* Vein with outer diameter \\\u003C3.5 mm or \\>8 mm under pressure.\n* Spliced Veins.\n* Known allergy to the cobalt-chromium alloy (ASTM 1058) or its components (Cobalt-Chromium-Iron-Nickel-Molybdenum).\n* Vasculitis\n* Coagulopathy\n* Radiation therapy near the anastomosis",{"count":53,"type":22},110,[55],"NA","The purpose of this clinical trial is to analyze patency after autologous infrainguinal bypass surgery in patients receiving a venous conduit versus a covered venous conduit.",[58,28,59,60,61],"Peripheral Arterial Occlusive Disease","Femoropopliteal Stenosis","Critical Limb-Threatening Ischemia","Claudication, Intermittent",[63,64,65],"Extraluminal Bypass Stenting","Autologous Vein Graft","Bypass Extremity Graft","RECRUITING","2023-11-20",{"date":69,"type":36},"2023-11-21",{"date":71,"type":36},"2023-09-11",{"date":73,"type":22},"2027-09",{"name":75,"class":43},"Paracelsus Medical University"]